Qsymia Alternatives & Comparison
Qsymia (phentermine and topiramate extended-release) set beside Contrave, Wegovy, Zepbound: how each works, what its trials measured, what it costs, and who sells it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
These are the drugs people weigh against Qsymia. The Qsymia drug guide covers Qsymia itself, the Qsymia cost page covers its price.
Qsymia Alternatives Compared
The main oral combination it gets compared against, also outside the GLP-1 class
Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, which release alpha-MSH to reduce appetite, but POMC neurons also release beta-endorphin, which feeds back onto mu-opioid receptors on the POMC neurons themselves and shuts them off — limiting the appetite-suppressing effect.
Insurers force this comparison more often than they admit. Qsymia is the more effective of the two (−9.8% to −10.9% at 56 weeks in CONQUER and EQUIP against Contrave's −6.1% in COR-I) and the cheaper, with generic phentermine plus topiramate from about $50 against Contrave's $99 program price. They work differently: Contrave on reward and craving, Qsymia on appetite and satiety. Both carry contraindications a GLP-1 does not.
Full Contrave vs Qsymia comparison →Trials put average weight loss substantially higher for this GLP-1 injection
Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake.
STEP-1 reported −14.9% at 68 weeks for Wegovy; EQUIP reported −10.9% at 56 weeks for Qsymia at its top 15/92 mg dose, which is closer than most people expect. Qsymia runs about $100–$200 a month, and generic phentermine plus topiramate can be around $50, against Wegovy's $349 through NovoCare. Topiramate carries real teratogenic risk, which is why the pregnancy questions on a Qsymia intake are not a formality.
Full Wegovy vs Qsymia comparison →Injection acting on GIP and GLP-1. No approved option averages more weight loss
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects.
About −20.9% at 72 weeks for Zepbound in SURMOUNT-1 against roughly −10.9% at 56 weeks for Qsymia in EQUIP, or −9.8% in CONQUER. Zepbound is $299–$449 through LillyDirect; Qsymia is $100–$200, and generic phentermine plus topiramate around $50. Half the effect for a fraction of the price is a real trade, and for someone paying cash indefinitely it is the one the arithmetic often favors.
Full Zepbound vs Qsymia comparison →The incretin-class route, if that is what you were after
Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours.
The pivotal trial was SCALE Obesity and Prediabetes (N=3,731 adults, none diabetic; Pi-Sunyer et al. NEJM 2015, PMID 26132939).
Drug facts on this page were last verified against each drug's FDA label and trial record.
Compare compounded Semaglutide providers
Compounded semaglutide sits at a middle figure of $199/month across 726 price points in the register, spanning $49 to $599. The partners below are ordered by our partner economics.
Compare compounded Tirzepatide providers
Compounded tirzepatide sits at a middle figure of $250/month across 697 price points in the register, spanning $69 to $849. The partners below are ordered by our partner economics.
Compare every Qsymia provider
Current price, verification status, product form and the states each seller ships to, all on one screen.